Published in J Virol on February 03, 2010
The latency-associated nuclear antigen, a multifunctional protein central to Kaposi's sarcoma-associated herpesvirus latency. Future Microbiol (2011) 1.13
Identification of host-chromosome binding sites and candidate gene targets for Kaposi's sarcoma-associated herpesvirus LANA. J Virol (2012) 1.05
mTOR inhibitors block Kaposi sarcoma growth by inhibiting essential autocrine growth factors and tumor angiogenesis. Cancer Res (2013) 1.04
Genomic analysis of xCT-mediated regulatory network: Identification of novel targets against AIDS-associated lymphoma. Oncotarget (2015) 1.02
A protein array screen for Kaposi's sarcoma-associated herpesvirus LANA interactors links LANA to TIP60, PP2A activity, and telomere shortening. J Virol (2012) 0.98
Targeting KSHV/HHV-8 latency with COX-2 selective inhibitor nimesulide: a potential chemotherapeutic modality for primary effusion lymphoma. PLoS One (2011) 0.97
Modulation of Immune System by Kaposi's Sarcoma-Associated Herpesvirus: Lessons from Viral Evasion Strategies. Front Microbiol (2012) 0.97
Treatment of Kaposi sarcoma-associated herpesvirus-associated cancers. Front Microbiol (2012) 0.97
Hsp90 inhibitors are efficacious against Kaposi Sarcoma by enhancing the degradation of the essential viral gene LANA, of the viral co-receptor EphA2 as well as other client proteins. PLoS Pathog (2012) 0.95
Phosphatase and tensin homolog on chromosome 10 is phosphorylated in primary effusion lymphoma and Kaposi's sarcoma. Am J Pathol (2011) 0.94
The DNA damage response in viral-induced cellular transformation. Br J Cancer (2012) 0.92
KSHV LANA--the master regulator of KSHV latency. Viruses (2014) 0.91
Kaposi's sarcoma-associated herpesvirus-encoded LANA recruits topoisomerase IIβ for latent DNA replication of the terminal repeats. J Virol (2012) 0.91
Epigenetic regulation of EBV and KSHV latency. Curr Opin Virol (2013) 0.90
Kaposi's sarcoma-associated herpesvirus-encoded LANA interacts with host KAP1 to facilitate establishment of viral latency. J Virol (2014) 0.89
Ribosomal protein S6 interacts with the latency-associated nuclear antigen of Kaposi's sarcoma-associated herpesvirus. J Virol (2011) 0.88
Phosphorylation of the chromatin binding domain of KSHV LANA. PLoS Pathog (2012) 0.88
Cytoplasmic isoforms of Kaposi sarcoma herpesvirus LANA recruit and antagonize the innate immune DNA sensor cGAS. Proc Natl Acad Sci U S A (2016) 0.87
At a crossroads: human DNA tumor viruses and the host DNA damage response. Future Virol (2011) 0.86
The viral latency-associated nuclear antigen augments the B-cell response to antigen in vivo. J Virol (2010) 0.85
NEDDylation is essential for Kaposi's sarcoma-associated herpesvirus latency and lytic reactivation and represents a novel anti-KSHV target. PLoS Pathog (2015) 0.84
Molecular biology of human herpesvirus 8: novel functions and virus-host interactions implicated in viral pathogenesis and replication. Recent Results Cancer Res (2014) 0.84
Kaposi's sarcoma-associated herpesvirus-encoded LANA contributes to viral latent replication by activating phosphorylation of survivin. J Virol (2014) 0.82
p53 tumor suppressor protein stability and transcriptional activity are targeted by Kaposi's sarcoma-associated herpesvirus-encoded viral interferon regulatory factor 3. Mol Cell Biol (2013) 0.81
Emmprin and KSHV: new partners in viral cancer pathogenesis. Cancer Lett (2013) 0.78
Kaposi sarcoma herpes virus latency associated nuclear antigen protein release the G2/M cell cycle blocks by modulating ATM/ATR mediated checkpoint pathway. PLoS One (2014) 0.78
Identification of Kaposi Sarcoma Herpesvirus (KSHV) vIRF1 Protein as a Novel Interaction Partner of Human Deubiquitinase USP7. J Biol Chem (2016) 0.76
Kaposi Sarcoma Herpesvirus (KSHV) Latency-Associated Nuclear Antigen (LANA) recruits components of the MRN (Mre11-Rad50-NBS1) repair complex to modulate an innate immune signaling pathway and viral latency. PLoS Pathog (2017) 0.75
Regulation of the Abundance of Kaposi's Sarcoma-Associated Herpesvirus ORF50 Protein by Oncoprotein MDM2. PLoS Pathog (2016) 0.75
KSHV-Mediated Angiogenesis in Tumor Progression. Viruses (2016) 0.75
Effects of the NEDD8-activating enzyme inhibitor MLN4924 on lytic reactivation of Kaposi's sarcoma-associated herpesvirus. J Virol (2017) 0.75
Ribonucleotide reductase represents a novel therapeutic target in primary effusion lymphoma. Oncogene (2017) 0.75
Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei. Nucleic Acids Res (1983) 124.30
p53 mutations in human cancers. Science (1991) 31.96
In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science (2004) 24.42
Mdm2 promotes the rapid degradation of p53. Nature (1997) 21.26
Regulation of p53 stability by Mdm2. Nature (1997) 18.20
T antigen is bound to a host protein in SV40-transformed cells. Nature (1979) 17.78
The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell (1992) 16.53
The promoter-specific transcription factor Sp1 binds to upstream sequences in the SV40 early promoter. Cell (1983) 15.09
Characterization of a 54K dalton cellular SV40 tumor antigen present in SV40-transformed cells and uninfected embryonal carcinoma cells. Cell (1979) 14.05
p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature (1993) 13.46
The IARC TP53 database: new online mutation analysis and recommendations to users. Hum Mutat (2002) 12.39
The p53-mdm-2 autoregulatory feedback loop. Genes Dev (1993) 11.19
The p53 pathway: positive and negative feedback loops. Oncogene (2005) 9.75
Direct activation of Bax by p53 mediates mitochondrial membrane permeabilization and apoptosis. Science (2004) 9.52
Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain. Science (1996) 9.48
Mdm2 is a RING finger-dependent ubiquitin protein ligase for itself and p53. J Biol Chem (2000) 6.92
Efficient persistence of extrachromosomal KSHV DNA mediated by latency-associated nuclear antigen. Science (1999) 5.55
p53 inhibition by the LANA protein of KSHV protects against cell death. Nature (2000) 4.74
Primary effusion lymphoma: a distinct clinicopathologic entity associated with the Kaposi's sarcoma-associated herpes virus. Blood (1996) 4.22
The latent nuclear antigen of Kaposi sarcoma-associated herpesvirus targets the retinoblastoma-E2F pathway and with the oncogene Hras transforms primary rat cells. Nat Med (2000) 4.20
Gain of function mutations in p53. Nat Genet (1993) 4.19
MDMX: a novel p53-binding protein with some functional properties of MDM2. EMBO J (1996) 4.13
p53 alteration is a common event in the spontaneous immortalization of primary BALB/c murine embryo fibroblasts. Genes Dev (1991) 4.01
Identification of the gene encoding the major latency-associated nuclear antigen of the Kaposi's sarcoma-associated herpesvirus. J Clin Invest (1997) 3.71
Limited transmission of Kaposi's sarcoma-associated herpesvirus in cultured cells. J Virol (1998) 3.54
The nucleosomal surface as a docking station for Kaposi's sarcoma herpesvirus LANA. Science (2006) 3.46
p53 and DNA polymerase alpha compete for binding to SV40 T antigen. Nature (1987) 3.34
The latency-associated nuclear antigen tethers the Kaposi's sarcoma-associated herpesvirus genome to host chromosomes in body cavity-based lymphoma cells. Virology (1999) 3.30
A novel viral mechanism for dysregulation of beta-catenin in Kaposi's sarcoma-associated herpesvirus latency. Nat Med (2003) 3.10
An intact HDM2 RING-finger domain is required for nuclear exclusion of p53. Nat Cell Biol (2000) 3.07
MDM2 interacts with MDMX through their RING finger domains. FEBS Lett (1999) 2.98
Nucleocytoplasmic shuttling of oncoprotein Hdm2 is required for Hdm2-mediated degradation of p53. Proc Natl Acad Sci U S A (1999) 2.89
Activity of MDM2, a ubiquitin ligase, toward p53 or itself is dependent on the RING finger domain of the ligase. Oncogene (2000) 2.84
Mouse p53 inhibits SV40 origin-dependent DNA replication. Nature (1987) 2.71
Wild-type p53 protein undergoes cytoplasmic sequestration in undifferentiated neuroblastomas but not in differentiated tumors. Proc Natl Acad Sci U S A (1995) 2.56
MdmX protects p53 from Mdm2-mediated degradation. Mol Cell Biol (2000) 2.50
DNA binding and modulation of gene expression by the latency-associated nuclear antigen of Kaposi's sarcoma-associated herpesvirus. J Virol (2001) 2.41
Latent nuclear antigen of Kaposi's sarcoma-associated herpesvirus interacts with RING3, a homolog of the Drosophila female sterile homeotic (fsh) gene. J Virol (1999) 2.36
Site-specific binding of wild-type p53 to cellular DNA is inhibited by SV40 T antigen and mutant p53. Genes Dev (1992) 2.29
Protein interactions targeting the latency-associated nuclear antigen of Kaposi's sarcoma-associated herpesvirus to cell chromosomes. J Virol (2002) 2.28
Latency-associated nuclear antigen (LANA) cooperatively binds to two sites within the terminal repeat, and both sites contribute to the ability of LANA to suppress transcription and to facilitate DNA replication. J Biol Chem (2002) 2.21
Modulation of cellular and viral gene expression by the latency-associated nuclear antigen of Kaposi's sarcoma-associated herpesvirus. J Virol (2001) 2.19
Human herpesvirus 8 LANA interacts with proteins of the mSin3 corepressor complex and negatively regulates Epstein-Barr virus gene expression in dually infected PEL cells. J Virol (2000) 2.17
Identification of a major latent nuclear antigen, LNA-1, in the human herpesvirus 8 genome. J Hum Virol (1999) 2.09
Levels of HdmX expression dictate the sensitivity of normal and transformed cells to Nutlin-3. Cancer Res (2006) 2.03
ORC, MCM, and histone hyperacetylation at the Kaposi's sarcoma-associated herpesvirus latent replication origin. J Virol (2004) 1.97
Carboxy terminus of human herpesvirus 8 latency-associated nuclear antigen mediates dimerization, transcriptional repression, and targeting to nuclear bodies. J Virol (2000) 1.96
Pharmacologic activation of p53 elicits Bax-dependent apoptosis in the absence of transcription. Cancer Cell (2003) 1.88
Differential regulation of the overlapping Kaposi's sarcoma-associated herpesvirus vGCR (orf74) and LANA (orf73) promoters. J Virol (2001) 1.84
Hdmx stabilizes Mdm2 and p53. J Biol Chem (2000) 1.81
Latency-associated nuclear antigen of Kaposi's sarcoma-associated herpesvirus (human herpesvirus-8) binds ATF4/CREB2 and inhibits its transcriptional activation activity. J Gen Virol (2000) 1.75
p53-mediated apoptosis of CLL cells: evidence for a transcription-independent mechanism. Blood (2008) 1.72
EC5S ubiquitin complex is recruited by KSHV latent antigen LANA for degradation of the VHL and p53 tumor suppressors. PLoS Pathog (2006) 1.71
Kaposi's sarcoma-associated herpesvirus LANA-1 interacts with the short variant of BRD4 and releases cells from a BRD4- and BRD2/RING3-induced G1 cell cycle arrest. J Virol (2006) 1.68
The transcriptional activity of cAMP response element-binding protein-binding protein is modulated by the latency associated nuclear antigen of Kaposi's sarcoma-associated herpesvirus. J Biol Chem (2001) 1.67
Disruption of Kaposi's sarcoma-associated herpesvirus latent nuclear antigen leads to abortive episome persistence. J Virol (2004) 1.64
The latency-associated nuclear antigen of Kaposi's sarcoma-associated herpesvirus modulates cellular gene expression and protects lymphoid cells from p16 INK4A-induced cell cycle arrest. J Biol Chem (2004) 1.64
Experimental transmission of Kaposi's sarcoma-associated herpesvirus (KSHV/HHV-8) to SCID-hu Thy/Liv mice. J Exp Med (1999) 1.61
Inhibiting primary effusion lymphoma by lentiviral vectors encoding short hairpin RNA. Blood (2004) 1.58
Acetylation of the latency-associated nuclear antigen regulates repression of Kaposi's sarcoma-associated herpesvirus lytic transcription. J Virol (2006) 1.57
Quantitative analyses reveal the importance of regulated Hdmx degradation for p53 activation. Proc Natl Acad Sci U S A (2007) 1.56
Human herpesvirus-8-encoded LNA-1 accumulates in heterochromatin- associated nuclear bodies. J Gen Virol (1999) 1.49
Functional integrity of the p53-mediated apoptotic pathway induced by the nongenotoxic agent nutlin-3 in B-cell chronic lymphocytic leukemia (B-CLL). Blood (2006) 1.49
Reactivation of the p53 pathway as a treatment modality for KSHV-induced lymphomas. J Clin Invest (2007) 1.49
The latency-associated nuclear antigen of Kaposi's sarcoma-associated herpesvirus transactivates the telomerase reverse transcriptase promoter. J Biol Chem (2001) 1.48
Induction of Kaposi's sarcoma-associated herpesvirus latency-associated nuclear antigen by the lytic transactivator RTA: a novel mechanism for establishment of latency. J Virol (2005) 1.47
Recruitment of the de novo DNA methyltransferase Dnmt3a by Kaposi's sarcoma-associated herpesvirus LANA. Proc Natl Acad Sci U S A (2006) 1.43
Kaposi's sarcoma-associated herpesvirus-encoded latency-associated nuclear antigen induces chromosomal instability through inhibition of p53 function. J Virol (2006) 1.36
Latent nuclear antigen of Kaposi's sarcoma herpesvirus/human herpesvirus-8 induces and relocates RING3 to nuclear heterochromatin regions. J Gen Virol (2002) 1.34
Characterization of monoclonal antibodies raised against the latent nuclear antigen of human herpesvirus 8. J Virol (1999) 1.32
Functional p53 signaling in Kaposi's sarcoma-associated herpesvirus lymphomas: implications for therapy. J Virol (2006) 1.32
KSHV targets multiple leukocyte lineages during long-term productive infection in NOD/SCID mice. J Clin Invest (2006) 1.29
The latency-associated nuclear antigen of Kaposi sarcoma-associated herpesvirus induces B cell hyperplasia and lymphoma. J Clin Invest (2006) 1.26
The latency-associated nuclear antigen encoded by Kaposi's sarcoma-associated herpesvirus activates two major essential Epstein-Barr virus latent promoters. J Virol (2001) 1.24
KSHV LANA1 binds DNA as an oligomer and residues N-terminal to the oligomerization domain are essential for DNA binding, replication, and episome persistence. Virology (2004) 1.24
Expression of p53 and human herpesvirus-8 (HHV-8)-encoded latency-associated nuclear antigen with inhibition of apoptosis in HHV-8-associated malignancies. Cancer (2001) 1.22
Transcriptional activation by the Kaposi's sarcoma-associated herpesvirus latency-associated nuclear antigen is facilitated by an N-terminal chromatin-binding motif. J Virol (2004) 1.21
The natural history and molecular heterogeneity of HIV-associated primary malignant lymphomatous effusions. J Acquir Immune Defic Syndr Hum Retrovirol (1996) 1.20
Persistent infection of Epstein-Barr virus-positive B lymphocytes by human herpesvirus 8. J Virol (1998) 1.19
Regulation and autoregulation of the promoter for the latency-associated nuclear antigen of Kaposi's sarcoma-associated herpesvirus. J Biol Chem (2004) 1.14
Determination of Kaposi's sarcoma-associated herpesvirus C-terminal latency-associated nuclear antigen residues mediating chromosome association and DNA binding. J Virol (2007) 1.09
Proteomic analysis of the Kaposi's sarcoma-associated herpesvirus terminal repeat element binding proteins. J Virol (2006) 1.04
Kaposi's sarcoma herpesvirus C-terminal LANA concentrates at pericentromeric and peri-telomeric regions of a subset of mitotic chromosomes. Virology (2006) 1.02
Definition of sequence requirements for latency-associated nuclear antigen 1 binding to Kaposi's sarcoma-associated herpesvirus DNA. J Virol (2004) 1.01
Targeted therapy for Kaposi's sarcoma and Kaposi's sarcoma-associated herpesvirus. Curr Opin Oncol (2007) 0.95
Stabilization of the tumor suppressor p53 during cellular transformation by simian virus 40: influence of viral and cellular factors and biological consequences. J Virol (1994) 0.95
Kaposi's sarcoma-associated herpesvirus latency-associated nuclear antigen induces a strong bend on binding to terminal repeat DNA. J Virol (2005) 0.93
ORF73 of herpesvirus saimiri, a viral homolog of Kaposi's sarcoma-associated herpesvirus, modulates the two cellular tumor suppressor proteins p53 and pRb. J Virol (2004) 0.91
Complex formation between the lymphotropic papovavirus large tumor antigen and the tumor suppressor protein p53. J Virol (1991) 0.88
Stability of p53 protein in rat cells transformed by various viral transforming genes. Virology (1992) 0.87
Circular RNAs are abundant, conserved, and associated with ALU repeats. RNA (2012) 5.16
INK4/ARF transcript expression is associated with chromosome 9p21 variants linked to atherosclerosis. PLoS One (2009) 2.77
Charting latency transcripts in Kaposi's sarcoma-associated herpesvirus by whole-genome real-time quantitative PCR. J Virol (2002) 2.71
EBV microRNAs in primary lymphomas and targeting of CXCL-11 by ebv-mir-BHRF1-3. Cancer Res (2008) 2.46
Expression of p16(INK4a) in peripheral blood T-cells is a biomarker of human aging. Aging Cell (2009) 2.21
Moving forward in HIV-associated cancer. J Clin Oncol (2014) 2.14
Rapamycin is efficacious against primary effusion lymphoma (PEL) cell lines in vivo by inhibiting autocrine signaling. Blood (2006) 1.83
In vivo-restricted and reversible malignancy induced by human herpesvirus-8 KSHV: a cell and animal model of virally induced Kaposi's sarcoma. Cancer Cell (2007) 1.68
SYBR green-based real-time quantitative PCR assay for detection of West Nile Virus circumvents false-negative results due to strain variability. J Clin Microbiol (2004) 1.64
Long-term-infected telomerase-immortalized endothelial cells: a model for Kaposi's sarcoma-associated herpesvirus latency in vitro and in vivo. J Virol (2006) 1.63
Dual inhibition of PI3K and mTOR inhibits autocrine and paracrine proliferative loops in PI3K/Akt/mTOR-addicted lymphomas. Blood (2010) 1.60
Toll-like receptor signaling controls reactivation of KSHV from latency. Proc Natl Acad Sci U S A (2009) 1.55
Pre-micro RNA signatures delineate stages of endothelial cell transformation in Kaposi sarcoma. PLoS Pathog (2009) 1.53
Immortalization of primary endothelial cells by the K1 protein of Kaposi's sarcoma-associated herpesvirus. Cancer Res (2006) 1.49
Early experience after developing a pathology laboratory in Malawi, with emphasis on cancer diagnoses. PLoS One (2013) 1.48
Faster quantitative real-time PCR protocols may lose sensitivity and show increased variability. Nucleic Acids Res (2005) 1.47
More on HIV-associated Kaposi's sarcoma. N Engl J Med (2008) 1.38
mda-7/IL-24, novel anticancer cytokine: focus on bystander antitumor, radiosensitization and antiangiogenic properties and overview of the phase I clinical experience (Review). Int J Oncol (2007) 1.34
Gene alteration and precursor and mature microRNA transcription changes contribute to the miRNA signature of primary effusion lymphoma. Blood (2007) 1.34
Functional p53 signaling in Kaposi's sarcoma-associated herpesvirus lymphomas: implications for therapy. J Virol (2006) 1.32
Dysregulation of fatty acid synthesis and glycolysis in non-Hodgkin lymphoma. Proc Natl Acad Sci U S A (2012) 1.32
Incidence and timing of cancer in HIV-infected individuals following initiation of combination antiretroviral therapy. Clin Infect Dis (2013) 1.31
Real-time quantitative PCR analysis of viral transcription. Methods Mol Biol (2005) 1.29
Interferon-γ production by neutrophils during bacterial pneumonia in mice. Am J Respir Crit Care Med (2010) 1.29
The tumor microenvironment controls primary effusion lymphoma growth in vivo. Cancer Res (2004) 1.28
The latency-associated nuclear antigen of Kaposi sarcoma-associated herpesvirus induces B cell hyperplasia and lymphoma. J Clin Invest (2006) 1.26
Reactivation of Kaposi's sarcoma-associated herpesvirus by natural products from Kaposi's sarcoma endemic regions. Int J Cancer (2007) 1.21
Azidothymidine inhibits NF-kappaB and induces Epstein-Barr virus gene expression in Burkitt lymphoma. Blood (2005) 1.14
Regulation and autoregulation of the promoter for the latency-associated nuclear antigen of Kaposi's sarcoma-associated herpesvirus. J Biol Chem (2004) 1.14
Potential pitfalls in microRNA profiling. Wiley Interdiscip Rev RNA (2012) 1.14
Role of Notch signal transduction in Kaposi's sarcoma-associated herpesvirus gene expression. J Virol (2005) 1.11
Tumor suppressor microRNAs are underrepresented in primary effusion lymphoma and Kaposi sarcoma. Blood (2009) 1.09
The molecular balancing act of p16(INK4a) in cancer and aging. Mol Cancer Res (2013) 1.08
Cigarette smoking induces small airway epithelial epigenetic changes with corresponding modulation of gene expression. Hum Mol Genet (2013) 1.08
mTOR inhibitors block Kaposi sarcoma growth by inhibiting essential autocrine growth factors and tumor angiogenesis. Cancer Res (2013) 1.04
Systemically circulating viral and tumor-derived microRNAs in KSHV-associated malignancies. PLoS Pathog (2013) 1.04
Expression profile of microRNAs in Epstein-Barr virus-infected AGS gastric carcinoma cells. J Virol (2013) 1.02
Tumor suppressor genes FHIT and WWOX are deleted in primary effusion lymphoma (PEL) cell lines. Blood (2011) 1.01
Comparison of the Rta/Orf50 transactivator proteins of gamma-2-herpesviruses. J Virol (2004) 1.00
Baboon model for West Nile virus infection and vaccine evaluation. Virology (2006) 0.99
Targeted next generation sequencing identifies clinically actionable mutations in patients with melanoma. Pigment Cell Melanoma Res (2014) 0.98
Tissue specificity of the Kaposi's sarcoma-associated herpesvirus latent nuclear antigen (LANA/orf73) promoter in transgenic mice. J Virol (2002) 0.98
Maribavir inhibits epstein-barr virus transcription in addition to viral DNA replication. J Virol (2009) 0.97
Liposomal daunorubicin as treatment for Kaposi's sarcoma. Int J Nanomedicine (2007) 0.97
Viral latency locus augments B-cell response in vivo to induce chronic marginal zone enlargement, plasma cell hyperplasia, and lymphoma. Blood (2013) 0.97
Pilot study of oral valganciclovir therapy in patients with classic Kaposi sarcoma. J Infect Dis (2011) 0.97
Generation of a human airway epithelium derived basal cell line with multipotent differentiation capacity. Respir Res (2013) 0.96
Hsp90 inhibitors are efficacious against Kaposi Sarcoma by enhancing the degradation of the essential viral gene LANA, of the viral co-receptor EphA2 as well as other client proteins. PLoS Pathog (2012) 0.95
Latent Kaposi's sarcoma-associated herpesvirus infection of monocytes downregulates expression of adaptive immune response costimulatory receptors and proinflammatory cytokines. J Virol (2012) 0.95
Phosphatase and tensin homolog on chromosome 10 is phosphorylated in primary effusion lymphoma and Kaposi's sarcoma. Am J Pathol (2011) 0.94
p16INK4a reporter mice reveal age-promoting effects of environmental toxicants. J Clin Invest (2013) 0.92
Methylene blue photoinactivation of RNA viruses. Antiviral Res (2004) 0.92
Novel Kaposi's sarcoma-associated herpesvirus homolog in baboons. J Virol (2003) 0.91
Vironome of Kaposi sarcoma associated herpesvirus-inflammatory cytokine syndrome in an AIDS patient reveals co-infection of human herpesvirus 8 and human herpesvirus 6A. Virology (2012) 0.90
Disruption of LANA in rhesus rhadinovirus generates a highly lytic recombinant virus. J Virol (2009) 0.90
An important role for mitochondrial antiviral signaling protein in the Kaposi's sarcoma-associated herpesvirus life cycle. J Virol (2014) 0.90
Tousled-like kinases modulate reactivation of gammaherpesviruses from latency. Cell Host Microbe (2013) 0.89
Ribosomal protein S6 interacts with the latency-associated nuclear antigen of Kaposi's sarcoma-associated herpesvirus. J Virol (2011) 0.88
De novo generation of CD4 T cells against viruses present in the host during immune reconstitution. Blood (2004) 0.88
Burkitt lymphoma in Brazil is characterized by geographically distinct clinicopathologic features. Am J Clin Pathol (2008) 0.88
Latency locus complements MicroRNA 155 deficiency in vivo. J Virol (2013) 0.88
General and target-specific RNA binding properties of Epstein-Barr virus SM posttranscriptional regulatory protein. J Virol (2009) 0.87
Smoking accelerates aging of the small airway epithelium. Respir Res (2014) 0.87
The open chromatin landscape of Kaposi's sarcoma-associated herpesvirus. J Virol (2013) 0.87
Profiling of pre-micro RNAs and microRNAs using quantitative real-time PCR (qPCR) arrays. J Vis Exp (2010) 0.87
Rapamycin with antiretroviral therapy in AIDS-associated Kaposi sarcoma: an AIDS Malignancy Consortium study. J Acquir Immune Defic Syndr (2012) 0.87
Promoter switching allows simultaneous transcription of LANA and K14/vGPCR of Kaposi's sarcoma-associated herpesvirus. Virology (2006) 0.87
Molecular and clinical assessment in the treatment of AIDS Kaposi sarcoma with valproic Acid. Clin Infect Dis (2009) 0.87
Development of a fluorescence-based assay to screen antiviral drugs against Kaposi's sarcoma associated herpesvirus. Mol Cancer Ther (2007) 0.86
Recent cancer incidence trends in an observational clinical cohort of HIV-infected patients in the US, 2000 to 2011. Infect Agent Cancer (2013) 0.86
The viral latency-associated nuclear antigen augments the B-cell response to antigen in vivo. J Virol (2010) 0.85
Methylene blue photoinactivation abolishes West Nile virus infectivity in vivo. Antiviral Res (2005) 0.83
Cytokine homologs of human gammaherpesviruses. J Interferon Cytokine Res (2011) 0.83
Kaposi sarcoma-associated herpesvirus: immunobiology, oncogenesis, and therapy. J Clin Invest (2016) 0.82
Relationship of immunologic response to antiretroviral therapy with non-AIDS defining cancer incidence. AIDS (2014) 0.81
Maribavir inhibits Epstein-Barr virus transcription through the EBV protein kinase. J Virol (2013) 0.80
Genome-wide real-time PCR for West Nile virus reduces the false-negative rate and facilitates new strain discovery. J Virol Methods (2010) 0.80
Viral latent proteins as targets for Kaposi's sarcoma and Kaposi's sarcoma-associated herpesvirus (KSHV/HHV-8) induced lymphoma. Curr Drug Targets Infect Disord (2003) 0.80
Nuclear factor kappa B pathway associated biomarkers in AIDS defining malignancies. Int J Cancer (2011) 0.80
Enhanced cytotoxicity without internuclear spread of adenovirus upon cell fusion by measles virus glycoproteins. J Virol (2005) 0.79
Efficiency clustering for low-density microarrays and its application to QPCR. BMC Bioinformatics (2010) 0.78
Rapalogs in viral cancers. Expert Opin Investig Drugs (2012) 0.78
Quantitative analysis of the bidirectional viral G-protein-coupled receptor and lytic latency-associated nuclear antigen promoter of Kaposi's sarcoma-associated herpesvirus. J Virol (2012) 0.78
A naturally occurring fatal case of Herpesvirus papio 2 pneumonia in an infant baboon (Papio hamadryas anubis). J Am Assoc Lab Anim Sci (2006) 0.78
Dual inhibition of phosphatidylinositol 3-kinase/mammalian target of rapamycin and mitogen activated protein kinase pathways in non-Hodgkin lymphoma. Leuk Lymphoma (2014) 0.78
Poisson factor models with applications to non-normalized microRNA profiling. Bioinformatics (2013) 0.77
AIDS related malignancies in Brazil. Curr Opin Oncol (2007) 0.77
Zidovudine-based lytic-inducing chemotherapy for Epstein-Barr virus-related lymphomas. Leuk Lymphoma (2013) 0.76
Correction: Type 2 Diabetes Risk Allele Loci in the Qatari Population. PLoS One (2016) 0.75
Brief Report: A Phase 1b/Pharmacokinetic Trial of PTC299, a Novel PostTranscriptional VEGF Inhibitor, for AIDS-Related Kaposi's Sarcoma: AIDS Malignancy Consortium Trial 059. J Acquir Immune Defic Syndr (2016) 0.75
Kaposi's sarcoma in Malawi: a continued problem for HIV-positive and HIV-negative individuals. AIDS (2017) 0.75
Reply to P. De Paoli et al. J Clin Oncol (2014) 0.75
Incomplete viral suppression and mortality in HIV patients after antiretroviral therapy initiation. AIDS (2017) 0.75
Chlamydia Trachomatis Seroprevalence and Ultrasound Diagnosed Uterine Fibroids in a Large Population of Young African-American Women. Am J Epidemiol (2017) 0.75